Platelet dysfunction in type 2 diabetes

被引:450
作者
Vinik, AI
Erbas, T
Park, TS
Nolan, R
Pittenger, GL
机构
[1] Eastern Virginia Med Sch, Strelitz Diabet Res Inst, Dept Med & Pathol Anat Neurobiol, Norfolk, VA 23501 USA
[2] Cato Res Ltd, Res Triangle Pk, NC USA
关键词
D O I
10.2337/diacare.24.8.1476
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin resistance is a uniform finding in type 2 diabetes, as are abnormalities in the microvascular and macrovascular circulations. These complications are associated with dysfunction Of platelets and the neurovascular unit. Platelets are essential for hemostasis, and knowledge of their function is basic to understanding the pathophysiology of vascular disease in diabetes. Intact health), vascular endothelium is central to the normal functioning of Smooth muscle contractility as well as its normal interaction with platelets. What is not clear is the role of hyperglycemia in the functional and organic microvascular deficiencies and platelet hyperactivity), in individuals with diabetes. The entire coagulation cascade is dysfunctional in diabetes, Increased levels of fibrinogen and plasminogen activator inhibitor I favor both thrombosis and defective dissolution of clots once formed. Platelets in type 2 diabetic individuals adhere to vascular endothelium and aggregate more readily than those in healthy people. Loss of sensitivity, to the normal restraints exercised by prostacyclin (PGI(2)) and nitric oxide (NO) generated by the vascular endothelium presents as the major defect in platelet function. Insulin is a natural antagonist of platelet hyperactivity. It sensitizes the platelet to PGI(2) and enhances endothelial generation of PGI(2) and NO. Thus, the defects in insulin action in diabetes create a milieu of disordered platelet activity conducive to macrovascular and microvascular events.
引用
收藏
页码:1476 / 1485
页数:10
相关论文
共 108 条
[11]   DECREASED PLATELET PHOSPHOINOSITIDE TURNOVER AND ENHANCED PLATELET ACTIVATION IN IDDM [J].
BASTYR, EJ ;
KADROFSKE, MM ;
DERSHIMER, RC ;
VINIK, AI .
DIABETES, 1989, 38 (09) :1097-1102
[12]  
BASTYR EJ, 1993, ONCOGENE, V8, P515
[13]  
BASTYR EJ, 1987, DIABETES S1, V36, pA208
[14]   PLATELET HYPERAGGREGATION AND INCREASED PLASMA-LEVEL OF VONWILLEBRAND FACTOR IN DIABETICS WITH RETINOPATHY [J].
BENSOUSSAN, D ;
LEVYTOLEDANO, S ;
PASSA, P ;
CAEN, J ;
CANIVET, J .
DIABETOLOGIA, 1975, 11 (04) :307-312
[15]   PLATELETS FROM DIABETIC SUBJECTS SHOW DIMINISHED SENSITIVITY TO PROSTACYCLIN [J].
BETTERIDGE, DJ ;
ELTAHIR, KEH ;
RECKLESS, JPD ;
WILLIAMS, KI .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1982, 12 (05) :395-398
[16]  
BONO MD, 1996, DIABETES S2, V45, pA65
[17]  
Brownlee M, 1990, ELLENBERG RIFKINS DI, P279
[18]  
BRUNNER D, 1984, CLIN THER, V6, P636
[19]   ADVANCED GLYCOSYLATION PRODUCTS QUENCH NITRIC-OXIDE AND MEDIATE DEFECTIVE ENDOTHELIUM-DEPENDENT VASODILATATION IN EXPERIMENTAL DIABETES [J].
BUCALA, R ;
TRACEY, KJ ;
CERAMI, A .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (02) :432-438
[20]   Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men [J].
Byberg, L ;
Siegbahn, A ;
Berglund, L ;
McKeigue, P ;
Reneland, R ;
Lithell, H .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (02) :258-264